pmid,title,journal,year,drug,disease
39985762,Disease-Drug-Drug Interaction of Imatinib in COVID-19 ARDS: A Pooled Population Pharmacokinetic Analysis.,CPT: pharmacometrics & systems pharmacology,2025,Imatinib,SARS-CoV-2
39748395,Integrative analyses of mendelian randomization and bioinformatics reveal casual relationship and genetic links between COVID-19 and knee osteoarthritis.,BMC medical genomics,2025,Imatinib,SARS-CoV-2
39587918,Evaluating imatinib in severe COVID-19: a systematic review and meta-analysis.,Transactions of the Royal Society of Tropical Medicine and Hygiene,2025,Imatinib,SARS-CoV-2
39519351,Vitamin K2 Protects Against SARS-CoV-2 Envelope Protein-Induced Cytotoxicity in Chronic Myeloid Leukemia Cells and Enhances Imatinib Activity.,International journal of molecular sciences,2024,Imatinib,SARS-CoV-2
39445010,Increased plasma imatinib exposure and toxicity in chronically treated GIST patients with SARS-CoV-2 infection: a case series.,Frontiers in immunology,2024,Imatinib,SARS-CoV-2
39281285,Gastrointestinal tract organoids as novel tools in drug discovery.,Frontiers in pharmacology,2024,Imatinib,SARS-CoV-2
39165680,Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report.,Frontiers in oncology,2024,Imatinib,SARS-CoV-2
39024368,"In-silico discovery of common molecular signatures for which SARS-CoV-2 infections and lung diseases stimulate each other, and drug repurposing.",PloS one,2024,Imatinib,SARS-CoV-2
38969238,Short- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial.,The Journal of infection,2024,Imatinib,SARS-CoV-2
38503318,"Drugs and natural products for the treatment of COVID-19 during 2020, the first year of the pandemic.",Boletin medico del Hospital Infantil de Mexico,2024,Imatinib,SARS-CoV-2
38454628,Pharmacist's role in the management of drug-drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients.,Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,2025,Imatinib,SARS-CoV-2
38424569,Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial.,"Critical care (London, England)",2024,Imatinib,SARS-CoV-2
38272877,Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients.,Nature communications,2024,Imatinib,SARS-CoV-2
38186640,"Identification of oral therapeutics using an AI platform against the virus responsible for COVID-19, SARS-CoV-2.",Frontiers in pharmacology,2023,Imatinib,SARS-CoV-2
38022239,Paradoxical Immune Reconstitution Inflammatory Syndrome in SARS-CoV-2 Infection After Improvement of Chemotherapy-Induced Aplasia.,Cureus,2023,Imatinib,SARS-CoV-2
38006751,Predictions based on inflammatory cytokine profiling of Egyptian COVID-19 with 2 potential therapeutic effects of certain marine-derived compounds.,International immunopharmacology,2024,Imatinib,SARS-CoV-2
37601670,Management of chronic myelogenous leukemia with COVID-19 and hepatitis B.,Frontiers in oncology,2023,Imatinib,SARS-CoV-2
37542399,"Predictors of Mortality among COVID-19 Patients Admitted to Intensive Care Units: A Single-Center Study in Tehran, Iran.",Archives of Iranian medicine,2022,Imatinib,SARS-CoV-2
37337067,SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia.,Journal of cancer research and clinical oncology,2023,Imatinib,SARS-CoV-2
36995225,Amuvatinib Blocks SARS-CoV-2 Infection at the Entry Step of the Viral Life Cycle.,Microbiology spectrum,2023,Imatinib,SARS-CoV-2
36986786,Evaluation of In Vitro and In Vivo Antiviral Activities of Vitamin D for SARS-CoV-2 and Variants.,Pharmaceutics,2023,Imatinib,SARS-CoV-2
36864189,"A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.",Cellular & molecular immunology,2023,Imatinib,SARS-CoV-2
36819815,COVID-19 in patients with chronic myeloid leukaemia on tyrosine kinase inhibitor therapy: a Honduran observational study.,Ecancermedicalscience,2022,Imatinib,SARS-CoV-2
36769193,"Evaluation of In Vitro Distribution and Plasma Protein Binding of Selected Antiviral Drugs (Favipiravir, Molnupiravir and Imatinib) against SARS-CoV-2.",International journal of molecular sciences,2023,Imatinib,SARS-CoV-2
36639911,"Baricitinib or imatinib in hospitalized COVID-19 patients: Results from COVINIB, an exploratory randomized clinical trial.",Journal of medical virology,2023,Imatinib,SARS-CoV-2
36522140,A leap towards personalised therapy of acute lung injury.,The European respiratory journal,2022,Imatinib,SARS-CoV-2
36312321,In silico investigation of the therapeutic and prophylactic potential of medicinal substances bearing guanidine moieties against COVID-19.,Chemicke zvesti,2023,Imatinib,SARS-CoV-2
36117402,Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.,Journal of medical virology,2023,Imatinib,SARS-CoV-2
35989789,Co-occurrence of CML Blast Crisis and Severe COVID 19 Infection: A Case Report.,Cureus,2022,Imatinib,SARS-CoV-2
35756668,Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19.,Frontiers in oncology,2022,Imatinib,SARS-CoV-2
35634954,"Artesunate, imatinib, and infliximab in COVID-19: A rapid review and meta-analysis of current evidence.","Immunity, inflammation and disease",2022,Imatinib,SARS-CoV-2
35460539,Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS-CoV-2 Infection: A Case Study With Imatinib.,Journal of clinical pharmacology,2022,Imatinib,SARS-CoV-2
35388061,Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism.,Scientific reports,2022,Imatinib,SARS-CoV-2
35255712,SARS-CoV-2 Infection Induces Ferroptosis of Sinoatrial Node Pacemaker Cells.,Circulation research,2022,Imatinib,SARS-CoV-2
35220926,In silico and in vitro evaluation of imatinib as an inhibitor for SARS-CoV-2.,Journal of biomolecular structure & dynamics,2023,Imatinib,SARS-CoV-2
35218499,What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?,Current oncology reports,2022,Imatinib,SARS-CoV-2
35172891,The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri(R)) in subjects with acute respiratory distress syndrome induced by COVID-19.,Trials,2022,Imatinib,SARS-CoV-2
35150639,Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry.,Cell metabolism,2022,Imatinib,SARS-CoV-2
35136710,Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking.,Network modeling and analysis in health informatics and bioinformatics,2022,Imatinib,SARS-CoV-2
35064248,A guide to immunotherapy for COVID-19.,Nature medicine,2022,Imatinib,SARS-CoV-2
34877907,Determining similarities of COVID-19 - lung cancer drugs and affinity binding mode analysis by graph neural network-based GEFA method.,Journal of biomolecular structure & dynamics,2023,Imatinib,SARS-CoV-2
34833917,Antiviral Activities of Halogenated Emodin Derivatives against Human Coronavirus NL63.,"Molecules (Basel, Switzerland)",2021,Imatinib,SARS-CoV-2
34668225,Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts.,Journal of cellular biochemistry,2022,Imatinib,SARS-CoV-2
34650951,Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.,Frontiers in public health,2021,Imatinib,SARS-CoV-2
34531332,Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials.,Aging,2021,Imatinib,SARS-CoV-2
34519259,Drug repositioning against COVID-19: a first line treatment.,Journal of biomolecular structure & dynamics,2022,Imatinib,SARS-CoV-2
34517025,Genomics-guided targeting of stress granule proteins G3BP1/2 to inhibit SARS-CoV-2 propagation.,International journal of biological macromolecules,2021,Imatinib,SARS-CoV-2
34437930,Antibody formation against SARS-CoV-2 in imatinib-treated COVID-19 patients.,The Journal of infection,2022,Imatinib,SARS-CoV-2
34327214,Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline.,Frontiers in molecular biosciences,2021,Imatinib,SARS-CoV-2
34311539,"Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2021,Imatinib,SARS-CoV-2
